Evidence map›Paper›PMID 36896209›Full record

ArticleAdvances in radiation oncology

High-Grade Glioma Radiation Therapy and Reirradiation Treatment Planning Using Translocator Protein Positron Emission Tomography With

Daniel Felix Fleischmann, Marcel Büttner, Marcus Unterrainer, Stefanie Corradini, Barbara Zollner, Jan Hofmaier, Raphael Bodensohn, Niklas Thon, Claus Belka, Peter Bartenstein and 2 more

Open access · goldAbstract read
In one paragraph

Article in Advances in radiation oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
  3. Longitudinal [Biomedicines · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Daniel Felix FleischmannDepartment of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany.
Marcel BüttnerDepartment of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany.
Marcus UnterrainerDepartment of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.
Stefanie CorradiniDepartment of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany.
Barbara ZollnerDepartment of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany.
Jan HofmaierDepartment of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany.
Raphael BodensohnDepartment of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany.
Niklas ThonDepartment of Neurosurgery, University Hospital, LMU Munich, Munich, Germany.
Claus BelkaDepartment of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany.
Peter BartensteinGerman Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany.
Nathalie L AlbertGerman Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany.
Maximilian NiyaziDepartment of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany.
LMU Klinikum · DEGerman Cancer Research Center · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Translocator protein (TSPO) positron emission tomography (PET) using Methods and Materials: The possible benefit of Results: Thirty-five primary RT and 16 reRT cases were examined. BTV1.6, BTV1.8, and BTV2.0 were significantly larger than corresponding cGTV volumes in primary RT (median volumes: 67.4, 50.7, and 39.1, respectively, vs 22.6 cm Conclusions:

Identifiers

PMID36896209
PMCPMC9991534
OpenAlexW4319992998

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.